DSIP vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | DSIP | Setmelanotide |
|---|---|---|
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |